Clinical Report: Exploring the Clinical Features and Proteomic Profile of Relapsing Polychondritis with Respiratory Complications
Overview
This study investigates the clinical characteristics and proteomic profiles of relapsing polychondritis (RP) patients with respiratory involvement. Key findings include distinct bronchoscopic manifestations and the role of complement and NETs-related proteins in the disease's pathogenesis.
Background
Relapsing polychondritis is a rare autoimmune disease that can lead to severe respiratory complications, significantly impacting patient mortality. Accurate diagnosis is often challenging due to overlapping symptoms with common respiratory conditions, resulting in misdiagnosis. Understanding the clinical features and underlying mechanisms of respiratory involvement in RP is crucial for improving patient outcomes.
Data Highlights
Clinical Feature
Group 1 & 2
Group 3
ICU Admission
Low
High (p = 0.003)
Tracheostomy
Low
High (p < 0.001)
Rescue Interventions
Low
High (p = 0.001)
Ear Chondritis
14.29%
42.86%
Nasal Chondritis
24.48%
46.43%
Ocular Involvement
16.33%
39.29%
Key Findings
Patients with respiratory involvement are less likely to have ear, nasal, or ocular chondritis.
Three subgroups of patients were identified based on bronchoscopic findings, indicating varying degrees of airway damage.
Group three patients exhibited a higher frequency of ICU admissions and tracheostomy requirements.
Complement and NETs-related proteins may play a role in the pathogenesis of respiratory-involved RP.
Recognition of specific imaging and bronchoscopic features can aid in the diagnosis of RP.
Clinical Implications
Clinicians should be aware of the nonspecific clinical manifestations of respiratory-involved RP and the importance of imaging and bronchoscopic evaluations for accurate diagnosis.
Conclusion
The study highlights the complexity of respiratory involvement in relapsing polychondritis.
Joint tenderness showed broader associations with concurrent ultrasound abnormalities than patient-reported pain among anti-cyclic citrullinated peptide–positive patients without clinical arthritis.
